title: Effect of suplatast tosilate, a Th2 cytokine inhibitor, on cough variant asthma.
abstract: OBJECTIVE
  Th2 cytokines play an important role in the pathogenesis of asthma. Our study objective was to determine the effect of suplatast tosilate, a Th2 cytokine inhibitor, on patients with cough-variant asthma.
  
  
  METHODS
  Twenty patients with cough-variant asthma (CVA) were assigned to a suplatast tosilate (100 mg three times daily) group or a placebo group for 6 weeks in a double-blind randomized study. The cough scores, medication scores, pulmonary function, bronchial hyperresponsiveness to methacholine, cough threshold for capsaicin, percentage of eosinophils and concentrations of eosinophilic cationic protein (ECP) in hypertonic saline-induced (induced) sputum were evaluated. The main outcome measures were capsaicin cough threshold and concentrations of ECP in induced sputum.
  
  
  RESULTS
  In the suplatast group, the cough scores and the medication scores decreased significantly over time. The percentage of eosinophils in induced sputum significantly decreased from 53.5+/-5.6% to 13.6+/-2.6%. The cough threshold for capsaicin improved significantly from 2.72+/-3.41 microM to 39.7+/-22.7 microM in the suplatast group. The concentrations of ECP in induced sputum decreased significantly from 435+/-123 microg/l to 56+/-34 microg/l in the suplatast group. The bronchial responsiveness to methacholine changed from 8.45+/-3.43 units to 11.4+/-3.76 units in the suplatast group.
  
  
  CONCLUSIONS
  Suplatast improved the cough scores and the cough threshold for capsaicin in patients with CVA without significant side effects, suggesting the effectiveness of suplatast in the treatment of CVA. Suplatast also decreased the percentage of eosinophils and concentrations of ECP in induced sputum, suggesting improvement in eosinophilic inflammation in patients with CVA. Further pharmacodynamic research is needed to explain the precise mechanism.
authors.affiliation: Department of Physical Therapy, Akita University College of Allied Medical Science, 1-1-1 Hondo, Akita, 010-8543, Japan. shioya@hos.akita-u.ac.jp
authors.forename: Takanobu
authors.initials: T
authors.lastname: Shioya
authors.forename: Masahiro
authors.initials: M
authors.lastname: Satake
authors.forename: Masaaki
authors.initials: M
authors.lastname: Sano
authors.forename: Manabu
authors.initials: M
authors.lastname: Kagaya
authors.forename: Akiko
authors.initials: A
authors.lastname: Watanabe
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Sato
authors.forename: Takeshi
authors.initials: T
authors.lastname: Ito
authors.forename: Nobuaki
authors.initials: N
authors.lastname: Ito
authors.forename: Masahiro
authors.initials: M
authors.lastname: Sasaki
authors.forename: Mamoru
authors.initials: M
authors.lastname: Miura
mesh_terms: D000328:Adult; D000368:Aged; D001190:Arylsulfonates / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy*; D003371:Cough / Q000188:drug therapy; D004311:Double-Blind Method; D004804:Eosinophils / Q000187:drug effects; D005260:Female; D006633:Histamine Antagonists / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D013183:Sputum / Q000187:drug effects; D013452:Sulfonium Compounds / Q000627:therapeutic use*; D018418:Th2 Cells / Q000187:drug effects
chemical_list: D001190:Arylsulfonates; D006633:Histamine Antagonists; D013452:Sulfonium Compounds; C073028:suplatast tosilate